Highlight
- Long-term lithium and valproate monotherapy significantly reduce suicide risk in bipolar disorder patients.
- Atypical antipsychotics, when combined with lithium or valproate, further decrease suicide incidence.
- The study utilizes a large nationwide Korean cohort with comprehensive real-world healthcare claims data.
- Findings underscore the importance of optimizing pharmacotherapy to reduce suicide attempts and deaths in bipolar disorder.
Study Background
